175 related articles for article (PubMed ID: 11050643)
21. MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement.
Guimaraes R; Clément O; Bittoun J; Carnot F; Frija G
AJR Am J Roentgenol; 1994 Jan; 162(1):201-7. PubMed ID: 8273666
[TBL] [Abstract][Full Text] [Related]
22. Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study.
Hudgins PA; Anzai Y; Morris MR; Lucas MA
AJNR Am J Neuroradiol; 2002 Apr; 23(4):649-56. PubMed ID: 11950660
[TBL] [Abstract][Full Text] [Related]
23. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience.
Bellin MF; Roy C; Kinkel K; Thoumas D; Zaim S; Vanel D; Tuchmann C; Richard F; Jacqmin D; Delcourt A; Challier E; Lebret T; Cluzel P
Radiology; 1998 Jun; 207(3):799-808. PubMed ID: 9609907
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of superparamagnetic iron-oxide MR contrast agents in the rat.
Majumdar S; Zoghbi SS; Gore JC
Invest Radiol; 1990 Jul; 25(7):771-7. PubMed ID: 2391194
[TBL] [Abstract][Full Text] [Related]
25. Visualization of superior mesenteric lymph nodes by the combined oral and intravenous administration of the ultrasmall superparamagnetic iron oxide, AMI-227.
Rogers JM; Lewis J; Josephson L
Magn Reson Imaging; 1994; 12(8):1161-5. PubMed ID: 7854022
[TBL] [Abstract][Full Text] [Related]
26. Use of USPIO-induced magnetic susceptibility artifacts to identify sentinel lymph nodes and lymphatic drainage patterns. I. Dependence of artifact size with subcutaneous Combidex dose in rats.
Rogers JM; Jung CW; Lewis J; Groman EV
Magn Reson Imaging; 1998 Oct; 16(8):917-23. PubMed ID: 9814774
[TBL] [Abstract][Full Text] [Related]
27. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent.
Bourrinet P; Bengele HH; Bonnemain B; Dencausse A; Idee JM; Jacobs PM; Lewis JM
Invest Radiol; 2006 Mar; 41(3):313-24. PubMed ID: 16481915
[TBL] [Abstract][Full Text] [Related]
28. Pelvic lymph node visualization with MR imaging using local administration of ultra-small superparamagnetic iron oxide contrast.
McCauley TR; Rifkin MD; Ledet CA
J Magn Reson Imaging; 2002 Apr; 15(4):492-7. PubMed ID: 11948841
[TBL] [Abstract][Full Text] [Related]
29. MR lymphography using iron oxide particles. Detection of lymph node metastases in the VX2 rabbit tumor model.
Taupitz M; Wagner S; Hamm B; Dienemann D; Lawaczeck R; Wolf KJ
Acta Radiol; 1993 Jan; 34(1):10-5. PubMed ID: 8427741
[TBL] [Abstract][Full Text] [Related]
30. Interstitial MR lymphography with iron oxide particles: results in tumor-free and VX2 tumor-bearing rabbits.
Taupitz M; Wagner S; Hamm B; Binder A; Pfefferer D
AJR Am J Roentgenol; 1993 Jul; 161(1):193-200. PubMed ID: 8517301
[TBL] [Abstract][Full Text] [Related]
31. MR lymphangiography: imaging strategies to optimize the imaging of lymph nodes with ferumoxtran-10.
Harisinghani MG; Dixon WT; Saksena MA; Brachtel E; Blezek DJ; Dhawale PJ; Torabi M; Hahn PF
Radiographics; 2004; 24(3):867-78. PubMed ID: 15143236
[TBL] [Abstract][Full Text] [Related]
32. MR relaxivity measurement of iron oxide nano-particles for MR lymphography applications.
Firouznia K; Amirmohseni S; Guiti M; Amanpour S; Baitollahi A; Kharadmand AA; Mohagheghi MA; Oghabian MA
Pak J Biol Sci; 2008 Feb; 11(4):607-12. PubMed ID: 18817134
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of an ultrasmall superparamagnetic iron oxide in MRI in a bone tumor model in rabbits.
Bush CH; Mladinich CR; Montgomery WJ
J Magn Reson Imaging; 1997; 7(3):579-84. PubMed ID: 9170045
[TBL] [Abstract][Full Text] [Related]
34. Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10, an ultrasmall superparamagnetic iron oxide.
Nishimura H; Tanigawa N; Hiramatsu M; Tatsumi Y; Matsuki M; Narabayashi I
J Am Coll Surg; 2006 Apr; 202(4):604-11. PubMed ID: 16571430
[TBL] [Abstract][Full Text] [Related]
35. USPIO (Ferumoxtran-10)-enhanced MRI to visualize reticuloendothelial system cells in neonatal rats: feasibility and biodistribution study.
Azoulay R; Olivier P; Baud O; Verney C; Santus R; Robert P; Gressens P; Sebag G
J Magn Reson Imaging; 2008 Oct; 28(4):1046-52. PubMed ID: 18821607
[TBL] [Abstract][Full Text] [Related]
36. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging.
Briley-Saebo K; Bjørnerud A; Grant D; Ahlstrom H; Berg T; Kindberg GM
Cell Tissue Res; 2004 Jun; 316(3):315-23. PubMed ID: 15103550
[TBL] [Abstract][Full Text] [Related]
37. Pelvic lymph node topography for radiotherapy treatment planning from ferumoxtran-10 contrast-enhanced magnetic resonance imaging.
Dinniwell R; Chan P; Czarnota G; Haider MA; Jhaveri K; Jewett M; Fyles A; Jaffray D; Milosevic M
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):844-51. PubMed ID: 19095369
[TBL] [Abstract][Full Text] [Related]
38. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging.
Weissleder R; Elizondo G; Wittenberg J; Lee AS; Josephson L; Brady TJ
Radiology; 1990 May; 175(2):494-8. PubMed ID: 2326475
[TBL] [Abstract][Full Text] [Related]
39. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization?
Harisinghani MG; Saksena MA; Hahn PF; King B; Kim J; Torabi MT; Weissleder R
AJR Am J Roentgenol; 2006 Jan; 186(1):144-8. PubMed ID: 16357394
[TBL] [Abstract][Full Text] [Related]
40. Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neck.
Anzai Y; McLachlan S; Morris M; Saxton R; Lufkin RB
AJNR Am J Neuroradiol; 1994 Jan; 15(1):87-94. PubMed ID: 7511324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
